To Evaluate the Pharmacokinetics and Safety of AD-208

• Status: Completed
• Trial end date: 2020-05-04
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate pharmacokinetics and safety of AD-208.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• Healthy male Adult aged between 19 to 50 at the time of screening visit

• Weight over 50kg and Body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2 at the time of screening visit

• No evidence of medical symptoms or signs of congenital or no chronic disease

Exclusion Criteria:

• If having a clinically significant disease or medical history for blood/tumor, genitourinary systen, liver/biliary system, kidney, respiratory system, alimentary system, endocrine system, immune system, cardiovascular system, nervous system, skin and psychical disorder, etc